"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 4 | 0 | 4 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 3 | 1 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 3 | 4 |
| 2020 | 0 | 1 | 1 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database. Curr Probl Cardiol. 2022 11; 47(11):101345.
-
Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. Am J Hematol. 2022 06 01; 97(6):E191-E194.
-
Treatment with the BCL-2/BCL-xL inhibitor senolytic drug ABT263/Navitoclax improves functional hyperemia in aged mice. Geroscience. 2021 10; 43(5):2427-2440.
-
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
-
Apoptotic Ablation of Platelets Reduces Atherosclerosis in Mice With Diabetes. Arterioscler Thromb Vasc Biol. 2021 03; 41(3):1167-1178.
-
Acceptor substrate determines donor specificity of an aromatic prenyltransferase: expanding the biocatalytic potential of NphB. Appl Microbiol Biotechnol. 2020 May; 104(10):4383-4395.
-
Prostaglandin E2, a postulated mediator of neurovascular coupling, at low concentrations dilates whereas at higher concentrations constricts human cerebral parenchymal arterioles. Prostaglandins Other Lipid Mediat. 2020 02; 146:106389.
-
Synthesis and identification of heteroaromatic N-benzyl sulfonamides as potential anticancer agents. Org Biomol Chem. 2019 09 28; 17(36):8391-8402.
-
Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention. Mol Carcinog. 2019 10; 58(10):1908-1918.
-
A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. Br J Dermatol. 2019 05; 180(5):964-965.